American Journal of Cardiology
Volume 98, Issue 12 , Pages 1641-1645 , 15 December 2006

Effect of Levosimendan on Ventricular Arrhythmias and Prognostic Autonomic Indexes in Patients With Decompensated Advanced Heart Failure Secondary to Ischemic or Dilated Cardiomyopathy

Received 28 April 2006 ,Revised 3 July 2006 ,Accepted 3 July 2006.

References 

  1. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen P. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42:43–51
  2. Mc Bride B, White M. Levosimendan: implications for clinicians. J Clin Pharmacol. 2003;43:1071–1081
  3. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96:423–426
  4. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93:1309–1312
  5. Singh BN, Lilleberg J, Saqndell EP, Ylönen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and III clinical studies in cardiac failure. Am J Cardiol. 1999;83(suppl):16I–20I
  6. Lilleberg J, Ylönen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J. 2004;38:80–84
  7. Leprán I, Papp JG. Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats. Eur J Pharmacol. 2003;464:171–176
  8. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Clin Pharmacol. 2000;35:664–669
  9. Grumman N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol. 1998;31:741–749
  10. Szabo BM, van Veldhuisen DJ, van der Veer N, Brouwer J, De Graeff PA, Crijns HJGM. Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 1997;79:978–980
  11. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003;107:1764–1769
  12. Pathak A, Curnier D, Fourcade J, Roncalli J, Stein PK, Hermant P, et al. QT dynamicity: a prognostic factor for sudden death in chronic heart failure. Eur J Heart Failure. 2005;7:269–275
  13. Haigney MC, Zareba W, Gentlesk PJ, Gentlesk PJ, Goldstein RE, Illovsky M, et al. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Implantation Trial (MADIT) II patients. J Am Coll Cardiol. 2004;44:1481–1487
  14. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222–2227
  15. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81–86
  16. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903–1912
  17. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  18. Livanis E, Flevari P, Theodorakis G, Kolokathis F, Leftheriotis D, Kremastinos DTh. Effect of biventricular pacing on heart rate variability in patients with chronic heart failure. Eur J Heart Fail. 2003;5:175–178
  19. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, et al. Sudden cardiac death in heart failure: the role of abnormal repolarization. Circulation. 1994;90:2534–2539
  20. Singh BN. CIBIS, MERIT-HF and COPERNICUS trial outcomes: do they complete the chapter on beta-adrenergic blockers as antiarrhythmic and antifibrillatory drugs?. J Cardiovasc Pharmacol Ther. 2001;6:107–110
  21. Singh JP, Musialek P, Sleight P, Davey P, Marinho M, Hart G. Effect of atenolol or metoprolol on waking hour dynamics of the QT interval in myocardial infarction. Am J Cardiol. 1998;81:924–926
  22. Hintze U, Mickley H, Moller M. Effects of beta-blockers on the relation between QT interval and heart rate in survivors of acute myocardial infarction. Ann Noninvas Electrocardiol. 1998;3:319–326
  23. Tuininga YS, van Veldhuisen DJ, Brouwer J, Haaksma J, Crijns HJ, Man in’t Veld AJ, et al. HRV in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J. 1994;72:509–513
  24. Cleland JGF, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105–110
  25. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients (A meta-analysis). Eur J Clin Pharmacol. 1994;46:191–196

PII: S0002-9149(06)01719-X

doi: 10.1016/j.amjcard.2006.07.043

American Journal of Cardiology
Volume 98, Issue 12 , Pages 1641-1645 , 15 December 2006

Article Tools

* Image Usage & Resolution